Short Summary
Samsung has filed an IPR petition challenging Telcom Ventures’ ’199 patent covering NFC‑based mobile payments. The petition asserts obviousness over the Jain and Dua publications and cites lack of commercial success. A stipulation limits further district‑court litigation if the review is instituted.
Detailed Summary
In Petition IPR2025-00972, Samsung Electronics America, Inc. challenges U.S. Patent No. 10,219,199, which claims a method for conducting financial transactions using a smartphone with separate short‑range (NFC) and licensed cellular interfaces. The petitioner contends that the claimed invention is obvious in view of the Jain (U.S. Pub. No. 2009/0069049) and Dua (U.S. Pub. No. 2006/0165060) references, which disclose NFC communication, biometric authentication, and separate cellular receipt of services, all publicly available before the patent’s priority date. Secondary considerations, including the patent owner’s lack of commercial success and the widespread prior art, are presented to bolster the obviousness argument. The petition includes a stipulation that, should the Board institute the review, Samsung will not pursue parallel district‑court actions.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Samsung Electronics America, Inc. et al. vs Telcom Ventures LLC is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
TOP GLORY TRADING GROUP INC. et al.vsCole Haan LLC et al.
Top Glory and DP Dream have filed an IPR petition challenging Cole Haan’s U.S. Patent 11,041,262 covering knitted shoe uppers. They assert that the claims are obvious over prior‑art references Dua, ’762, ’288, Flusser and Litke, and that ornamental features lack patentable weight.
Cisco Systems, Inc.vsQPRIVACY USA LLC
The USPTO denied Cisco’s request for rehearing of the Director’s discretionary denial and institution denial in two IPRs involving QPRIVACY USA’s patent 11,106,824. The order upholds the earlier decisions.
Sun Pharmaceutical Industries, Inc.vsBiofrontera Inc.
Sun Pharmaceutical has filed a post‑grant review petition seeking cancellation of all 17 claims of Biofrontera’s nanoemulsion patent, alleging anticipation and obviousness over the Uhlmann and Palazzolo prior‑art references.
Qorvo, Inc.vsCornell Research Foundation Inc.
Qorvo challenges 24 claims of a semiconductor fabrication patent (7250360) in an IPR petition, asserting that the claimed epitaxial growth and nucleation processes are obvious. The petitioner relies on multiple combinations of prior art references including Urashima, Guo, Nagata, Keiper, and Manabe to demonstrate lack of novelty.
OnePlus Technology (Shenzhen) Co., Ltd. et al.vsPantech Corporation
The PTAB issued an institution decision in the OnePlus vs. Pantech IPR, finding reasonable likelihood that certain claims are unpatentable under 35 U.S.C. § 103. The Board's analysis hinged on detailed claim construction and the obviousness arguments presented against various 3GPP specifications and industry standards like Ericsson.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.